Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:12 PM
Ignite Modification Date:
2025-12-24 @ 2:12 PM
NCT ID:
NCT00955695
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed non-small cell lung cancer
* Stage IIIB or IV disease
* Must have had ≥ 8 weeks of gefitinib or erlotinib hydrochloride therapy
* At least 12 weeks of complete response or partial response since starting gefitinib or erlotinib hydrochloride
* Stable disease allowed provided 1 of the following criteria is met:
* EGFR mutation (exon 19 or 21)
* Having ≥ 2 of the following 3 factors:
* Female
* Never smoked
* Histologically confirmed adenocarcinoma of the lung
* No evidence of brain metastases by CT scan or MRI within the past 4 weeks
PATIENT CHARACTERISTICS:
* ECOG performance status 0-2
* ANC ≥ 1,500/mm\^3
* Platelet count ≥ 150,000/mm\^3
* Bilirubin \< 1.5 mg/dL
* Serum creatinine \< 1.5 times upper limit of normal
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* Received 1 or 2 prior systemic chemotherapy regimens
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00955695
Study Brief:
Protocol Section:
NCT00955695